Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 901–1,000 of 1,001
Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies
Zhang, Z., Wang, H., Li, M., Rayburn, E. R., Agrawal, S., & Zhang, R. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1359.030 · Cited by 24
Neilsen, P. M., Pehere, A. D., Pishas, K. I., Callen, D. F., & Abell, A. D. (2012) · ACS Chemical Biology · doi:10.1021/cb300549d · Cited by 27
Variable expressivity of the tumour suppressor protein TRP53 in cryopreserved human blastocysts
Chandrakanthan, V., Chami, O., Stojanov, T., & O’Neill, C. (2007) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-5-39 · Cited by 22
MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury
Thomasová, D., Ebrahim, M., Fleckinger, K., Li, M., Molnar, J., Popper, B., Liapis, H., Kotb, A. M., Siegerist, F., Endlich, N., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.390 · Cited by 21
MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation
Grochola, L. F., Müller, T. H., Bond, G. L., Taubert, H. W., Udelnow, A., & Würl, P. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181b9f105 · Cited by 25
“Besides such somatic mutations, the p53 stress response can be attenuated by aberrant expression of p53 regulatory genes such as the proto-oncogene MDM2.(5,6) The MDM2 protein is a key negative regulator of p53 and inhibits its function by regulating its cellular location, stability, and ability to regulate transcript…”
BackgroundMDM2 as a Critical Effector of the MYCN Oncogene in Tumorigenesis
Slack, A., & Shohet, J. M. (2005) · Cell Cycle · doi:10.4161/cc.4.7.1790 · Cited by 22
Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis
Chen, Y.-C., Lin-Shiau, S.-Y., & Lin, J.-K. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199811)177:2<324::aid-jcp14>3.0.co;2-9 · Cited by 465
Characterization of the 5′ and 3′ untranslated regions in murine mdm2 mRNAs
Mendrysa, S. M., McElwee, M. K., & Perry, M. E. (2001) · Gene · doi:10.1016/s0378-1119(00)00589-8 · Cited by 22
Lozano, G., & Luna, R. M. D. O. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00037-1 · Cited by 46
Self-citationThe phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation
Cheng, Q., & Chen, J. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15249 · Cited by 21
“However, current evidence suggests that MDM2 is a major and indispensable regulator of p53 level.(7,8) Elucidating how p53 is stabilized and activated after DNA damage is the subject of many studies.”
BackgroundParadis, F.-H., & Hales, B. F. (2015) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21149 · Cited by 22
Guardian of corpulence: a hypothesis on p53 signaling in the fat cell
Bazuine, M., Stenkula, K. G., Cam, M., Arroyo, M., & Cushman, S. W. (2009) · Clinical Lipidology · doi:10.2217/clp.09.2 · Cited by 22
The MDM2–p53 pathway: multiple roles in kidney development
El-Dahr, S. S., Hilliard, S. A., Aboudehen, K., & Saifudeen, Z. R. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2629-y · Cited by 21
“Genetic evidence that tight control of p53 by MDM2 is crucial for normal embryogenesis is indicated by the fact that p53 deletion rescues the embryonic lethality in MDM2 - and MDM4 -deficient mice [46, 47] and XRCC4 deficient mice [48].”
BackgroundCorcoran, C. A., Montalbano, J., Hong, S., He, Q., Huang, Y. K., & Sheikh, M. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.024232 · Cited by 23
The ARF‐p16 Gene Locus in Carcinogenesis and Therapy of Head and Neck Squamous Cell Carcinoma
Yarbrough, W. G. (2002) · The Laryngoscope · doi:10.1097/00005537-200212000-00002 · Cited by 23
“Deletion of the MDM2 gene in mice results in early embryonic lethality that can be rescued by the simultaneous deletion of the p53 gene, indicating that p53 is the major target of MDM2 during development.(25,26)”
BackgroundDistinct downstream targets manifest p53-dependent pathologies in mice
Pant, V, Xiong, S., Chau, G., Tsai, K., Shetty, G., & Lozano, G. (2016) · Oncogene · doi:10.1038/onc.2016.111 · Cited by 21
Self-citationEffect of potential role of p53 on embryo development arrest induced by H2O2 in mouse
De-bao, H., Li, Z., Ali, I., Xu, L., & Nan-zhu, F. (2017) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-016-0122-1 · Cited by 21
“It has been previously reported that p53 serine phosphorylation involves the MDM2-mediated pathway caused by p53 accumulation and development blocking (de Montes et al. 1995; Jin et al. 2009).”
BackgroundMDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis
Huang, Q., Chen, L., Yang, L., Xie, X., Gan, L., Cleveland, J. L., & Chen, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719090115 · Cited by 24
Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death
Singh, K. K., Shukla, P. C., Quan, A., Lovren, F., Pan, Y., Wolfstadt, J. I., Gupta, M., Al-Omran, M. A., Leong-Poi, H. M., Teoh, H., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.169 · Cited by 21
Therapeutic targeting of the p53 tumor suppressor gene
Beaudry, G. A. (1996) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(96)80069-3 · Cited by 21
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma
Hsieh, C., & Shen, C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0622-9 · Cited by 21
Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program
Pant, V., Sun, C., & Lozano, G. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01123-2 · Cited by 26
“Loss of Mdm2 in mice leads to embryonic lethality at pre-implantation due to induction of apoptosis, a phenotype that is rescued by the concomitant deletion of p53 [50, 51].”
BackgroundSelf-citationMDM2 inhibitors in cancer immunotherapy: Current status and perspective
Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 25
Ubiquitin Ligases in Cancer: Ushers for Degradation
Newton, K., & Vucic, D. (2007) · Cancer Investigation · doi:10.1080/07357900701508041 · Cited by 21
“Mdm2 is essential for keeping p53 in check during mouse embryo development because the early embryonic lethality caused by loss of Mdm2 does not occur in the absence of p53 (54, 55).”
BackgroundMouse modelling of the MDM2/MDMX−p53 signalling axis
Tackmann, N. R., & Zhang, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx006 · Cited by 23
“However, the degree of MDM2 importance to p53 regulation was not fully appreciated until the creation of Mdm2 deletion alleles in the mouse (Montes de Oca Luna et al., 1995; Jones et al., 1995).”
BackgroundMDM2 and mitochondrial function: One complex intersection
Rubio‐Patiño, C., Trotta, A. P., & Chipuk, J. E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.032 · Cited by 21
“The first literature describing genetic regulation of Mdm2 expression in vivo was the creation of Mdm2 null mice, which exhibit embryonic lethality, unless trp53 is conjointly deleted (Itahana et al., 2007; Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundVolk, E. L., Schuster, K., Nemeth, K. M., Fan, L., & Harris, L. C. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000992 · Cited by 20
Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
Hayano, T., Yokota, Y., Hosomichi, K., Nakaoka, H., Yoshihara, K., Adachi, S., Kashima, K., Tsuda, H., Moriya, T., Tanaka, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114491 · Cited by 19
Han, X., Medeiros, L. J., Zhang, Y. H., You, M. J., Andreeff, M., Konopleva, M. Y., & Bueso-Ramos, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.03.012 · Cited by 20
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 24
Modification of MDMX by sumoylation
Pan, Y., & Chen, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.012 · Cited by 23
Organization, expression, and localization of the murine mdmx gene and pseudogene
Parant, J. M., Reinke, V., Mims, B. H., & Lozano, G. (2001) · Gene · doi:10.1016/s0378-1119(01)00432-2 · Cited by 29
Self-citationSchmid, G., Kramer, M. P., Maurer‐Granofszky, M., Wandl, S., & Węsierska‐Gądek, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21383 · Cited by 20
“Strikingly, the importance of Mdm2 for p53 regulation is underscored by the fact thatMdm2 deficiency is able to rescue the embryonic lethality of p53 knock-out mice [Jones et al., 1995; Montes de Oca Luna et al., 1995].”
BackgroundDey, D. C., Bronson, R. T., Dahl, J., Carroll, J. P., & Benjamin, T. L. (2000) · PubMed · Cited by 20
Regulation of p53-dependent transcription
Jõers, A. (2004) · DSpace repository (University of Tartu) · Cited by 220
Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor–Host Feedback Signaling
Kamer, I., Daniel‐Meshulam, I., Zadok, O., Bab-Dinitz, E., Perry, G., Feniger-Barish, R., Perelman, M., Barshack, I., Ben‐Nun, A., Onn, A., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0395 · Cited by 20
“MDM2 has a critical role as a negative regulator of p53, as demonstrated by embryonic lethality of MDM2-knockout mice that is completely rescued by TP53 knockout (25, 26).”
BackgroundSynthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Ivanenkov, Y. A., Kukushkin, M. E., Beloglazkina, A. A., Shafikov, R. R., Barashkin, A. A., Ayginin, A. A., Serebryakova, M. S., Majouga, A. G., Skvortsov, D. A., Тафеенко, В. А., et al. (2023) · Molecules · doi:10.3390/molecules28031325 · Cited by 20
“In contrast to p53, the depletion of MDM2 in mice ultimately leads to lethal outcomes [7].”
BackgroundJmjd5 functions as a regulator of p53 signaling during mouse embryogenesis
Ishimura, A., Terashima, M., Tange, S., & Suzuki, T. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2276-7 · Cited by 19
Riley, M. F., You, M. J., Multani, A. S., & Lozano, G. (2015) · Oncogene · doi:10.1038/onc.2015.88 · Cited by 20
“Loss of Mdm2 leads to an embryonic lethal phenotype that is p53-dependent [5, 6].”
BackgroundSelf-citationMouse models of Mdm2 and Mdm4 and their clinical implications
Xiong, S. (2013) · 癌症:英文版 · doi:10.5732/cjc.012.10286 · Cited by 23
“Strategies to block p53 and Mdm4 interaction are also under intensive investigation[12,13].”
BackgroundMDM2 controls gene expression independently of p53 in both normal and cancer cells
Arena, G., Riscal, R., Linares, L. K., & Cam, L. L. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0156-x · Cited by 21
Overexpression of SCYL1‐BP1 stabilizes functional p53 by suppressing MDM2‐mediated ubiquitination
Yan, J. Y., Di, Y., Shi, H., et al. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.09.019 · Cited by 19
Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2
Heyne, K., Förster, J., Schüle, R., & Roemer, K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1371 · Cited by 19
p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction
Medina‐Medina, I., Martínez‐Sánchez, M., Hernández‐Monge, J., Fåhræus, R., Müller, P., & Olivares‐Illana, V. (2018) · Protein Science · doi:10.1002/pro.3405 · Cited by 21
“nonredundant paralogous proteins, HDM2 and HDMX (MDM2 and MDMX in mice).(4,5) HDM2 is an E3 ubiquitin ligase carrying a C-terminal RING (Really Interesting New Gene) domain, whereas HDMX lacks this activity despite sharing 75% overall similarity in this region.”
BackgroundNew targets for the treatment of follicular lymphoma
Tageja, N., Padheye, S., Dandawate, P. R., Al-Katib, A. M., & Mohammad, R. M. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-50 · Cited by 20
“Deletion of MDM2 gene in mice is lethal, but can only be reversed by simultaneous deletion of the TP53 gene [63,64].”
BackgroundTamm, K. P., Okan, İ., Kashuba, E., L√∂wbeer, M., Klein, G., & Székely, L. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-4-987 · Cited by 21
“Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. (1995).”
BackgroundYang, H. L., Dong, Y., Elliott, M. J., Wong, S. L., & McMasters, K. M. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700301 · Cited by 19
Targeting HAUSP in both p53 wildtype and p53-mutant tumors
Tavana, O., Sun, H., & Gu, W. J. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1456293 · Cited by 20
“phenotype was completely rescued by p53 ablation [13,14], the lethality observed from the Hausp mutant mice were not rescued by p53 inactivation [11,12].”
BackgroundInactivation of p53 Is Insufficient to Allow B Cells and B-Cell Lymphomas to Survive Without Dicer
Adams, C. M., & Eischen, C. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1866 · Cited by 19
“21), and p53 À/À mice from Dr. Guillermina Lozano (University of Texas M.D. Anderson Cancer Center, Houston, TX; ref.”
Walter, R. F. H., Vollbrecht, C., Werner, R., Mairinger, T., Schmeller, J., Flom, E., Wohlschlaeger, J., Barbetakis, N. G., Paliouras, D., Chatzinikolaou, F. G., et al. (2016) · Journal of Cancer · doi:10.7150/jca.16390 · Cited by 20
Review and Literature Mining on Proteostasis Factors and Cancer
Carvalho, A. S., Rodríguez, M. S., & Matthiesen, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3756-1_2 · Cited by 20
RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
Lee, J.-W., van Wijnen, A. J., & Bae, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_20 · Cited by 21
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes
Ortiz, J., Li, Y., Post, S. M., Pant, V., Xiong, S., Larsson, C. A., El‐Naggar, A. K., Johnson, D. G., & Lozano, G. (2017) · Oncogene · doi:10.1038/onc.2017.344 · Cited by 18
“In vivo studies have concluded that Mdm2 is a potent negative regulator of tumor suppressor p53 protein; mouse models with homozygous Mdm2 deletions exhibit embryonic lethality, a phenotype that is entirely rescued by p53 deletion [43, 44].”
Self-citationX-Linked Huwe1 Is Essential for Oocyte Maturation and Preimplantation Embryo Development
Eisa, A. A., Bang, S., Crawford, K. J., Murphy, E. M., Feng, W. W., Dey, S., Wells, W. A., Kon, N., Gu, W. J., Mehlmann, L. M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101523 · Cited by 18
Loss of tumor protein 53 protects against alcohol‐induced facial malformations in mice and zebrafish
Fish, E. W., Tucker, S. K., Peterson, R. L., Eberhart, J. K., & Parnell, S. E. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14688 · Cited by 19
Cell Death and the p53 Enigma During Mammalian Embryonic Development
Raj, S., Jaiswal, S. K., & Depamphilis, M. (2022) · Stem Cells · doi:10.1093/stmcls/sxac003 · Cited by 26
Hav, M., Libbrecht, L. J., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M. M., & Pauwels, P. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1012-7 · Cited by 20
“The importance of MDM2 in p53 regulation was shown in vivo by the lethality of MDM2−/− embryos at 3.5 days post coitum whereas p53−/−MDM2−/− mice develop without abnormalities [11, 12 ].”
BackgroundInfluentialSelective protein degradation in cell signalling
Liu, H., Urbé, S., & Clague, M. J. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.014 · Cited by 19
“[97] Montes de Oca Luna R, Wagner DS, Lozano G.”
Backgroundp53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy
Rodriguez-Ramirez, C., & Nor, J. E. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027353 · Cited by 17
Developmental noise, ageing and cancer
Aranda‐Anzaldo, A., & Dent, M. A. R. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00089-7 · Cited by 20
The ubiquitin–protein ligase activity of Hdm2 is inhibited by nucleic acids
Linares, L. K., & Scheffner, M. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01108-6 · Cited by 21
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality
Luna, R. M. D. O., Amelse, L. L., Chávez‐Reyes, A., Evans, S. C., Brugarolas, J., Jacks, T., & Lozano, G. (1997) · Nature Genetics · doi:10.1038/ng0897-336 · Cited by 20
Self-citationLassus, P., Bertrand‐Gaday, C., Zugasti, O., Chambon, J., Soussi, T., Mathieu-Mahul, D., & Hibner, U. (1999) · Oncogene · doi:10.1038/sj.onc.1202841 · Cited by 20
“Expression of the tumour suppressor p53 is tightly controlled during embryonic development and in the adult (Gottlieb et al., 1997; Komarova et al., 1997; Montes de Oca Luna et al., 1995; Schmid et al., 1991).”
BackgroundProtein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
Marques, M. A., de Andrade, G. C., Silva, J. L., & de Oliveira, G. A. P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.944955 · Cited by 16
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 19
Modulation of the p53 family network by RNA-binding proteins
Lucchesi, C. A., Zhang, J., & Chen, X. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.30 · Cited by 19
“The importance of strict p53 protein regulation is underscored by the fact that too much p53 leads to premature ageing (25) and cell death due to excessive apoptosis (26), whereas too little p53 has been shown to be a key aspect of tumorigenesis (27).”
BackgroundInhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
Kon, N., Wang, D., Li, T., Jiang, L., Qiang, L., & Gu, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23837 · Cited by 17
“Importantly, the lethality of mdm2 and mdmx knockout mice are rescued by concomitant deletion of p53, suggesting that Mdm2 and Mdmx exert their functions mainly through negative regulation of p53 [17-19].”
BackgroundMDM2 Overexpression, Activation of Signaling Networks, and Cell Proliferation
Deb, S. P., Singh, S., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_12 · Cited by 20
Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection
Yang, H., Zheng, Z., Zhao, L., Li, Q., & Liao, D. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19052 · Cited by 19
Livera, G., Uzbekov, R. E., Jarrier-Gaillard, P., Fouchécourt, S., Duquenne, C., Parent, A., Marine, J., & Monget, P. (2016) · FEBS Letters · doi:10.1002/1873-3468.12275 · Cited by 17
Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development
Laos, M., Sulg, M., Herranen, A., Anttonen, T., & Pirvola, U. (2017) · Scientific Reports · doi:10.1038/srep42216 · Cited by 18
Enhancers and Suppressors of Testicular Cancer Susceptibility in Single- and Double-Mutant Mice
Lam, M.-Y., Youngren, K. K., & Nadeau, J. H. (2004) · Genetics · doi:10.1093/genetics/166.2.925 · Cited by 20
Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16
MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging
Grieb, B. C., & Eischen, C. M. (2022) · Biology · doi:10.3390/biology11060881 · Cited by 18
Yan, J. Y., Zhang, D., Di, Y., Shi, H., Rao, H., & Huo, K. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.027 · Cited by 16
“Lozano [14].”
Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 18
Walter, R. F. H., Vollbrecht, C., Werner, R., Wohlschlaeger, J., Christoph, D. C., Schmid, K. W., & Mairinger, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.7666 · Cited by 19
Kosztyu, P., Slaninová, I., Valčíková, B., Verlande, A., Müller, P., Palecek, J. J., & Uldrijan, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00390 · Cited by 16
Egorova, O., Lau, H. H., McGraphery, K., & Sheng, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041309 · Cited by 20
Grawenda, A. M., Møller, E. K., Lam, S., Repapi, E., Teunisse, A. F. A. S., Alnæs, G. I. G., Børresen‐Dale, A., Kristensen, V. N., Goding, C. R., Jochemsen, A. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2637 · Cited by 16
Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides
Wei, S. J., Chee, S. M. Q., Yurlova, L., Lane, D. P., Verma, C. S., Brown, C. J., & Ghadessy, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8572 · Cited by 16
“Mouse embryonic fibroblast p53/Mdm2 double-knockout (DKO) cells (a kind gift from Guillermina Lozano) [58] were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) foetal calf serum (FCS) and 1% (v/v) penicillin/streptomycin.”
Retinoblastoma Binding Protein 6, Another p53 Monitor
Ntwasa, M. M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.003 · Cited by 16
Mdm2 mediates FMRP- and Gp1 mGluR-dependent protein translation and neural network activity
Liu, D.-C., Seimetz, J. W., Lee, K. Y., Kalsotra, A., Chung, H. J., Lu, H., & Tsai, N. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx276 · Cited by 21
“We used heterozygous mice (Mdm2f/þ) to avoid potential apoptosis caused by complete Mdm2 knockout (48,49).”
MethodExpression of mdm2 and p53 in epithelial neoplasms of the colorectum
Hao, X., Gunther, T., Roessner, A., Price, A. B., & Talbot, I. C. (1998) · Molecular Pathology · doi:10.1136/mp.51.1.26 · Cited by 16
Lysine-Independent Turnover of Cyclin G1 Can Be Stabilized by B′α Subunits of Protein Phosphatase 2A
Li, H., Okamoto, K., Peart, M. J., & Prives, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00907-08 · Cited by 21
Bao‐Lei, T., Zhuzhong, M., Song, Y., Jun‐Jie, Q., Yan, D., Hua, L., Bin, L., Zhao, G., & Zhi‐Xian, S. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20584 · Cited by 18
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
The Role of E3 Ligase Pirh2 in Disease
Daks, A. A., Fedorova, O., Parfenyev, S. E., Nevzorov, I. A., Shuvalov, O. Y., & Barlev, N. A. (2022) · Cells · doi:10.3390/cells11091515 · Cited by 21
“Importantly, mice with knockout of the RCHY1 gene encoding Pirh2 are viable, in contrast to Mdm2 knockout, which are lethal [83,84].”
BackgroundMLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis
Fang, D., Hu, H. Q., Zhao, K., Xu, A., Yu, C., Zhu, Y., Yu, N., Yao, B., Tang, S., Wu, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202303336 · Cited by 15
Kook, S., Gurevich, V. V., & Gurevich, E. V. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-41199-1_16 · Cited by 16
“The key importance of p53 for survival and Mdm2 for its regulation is strongly supported by the fact that mice lacking Mdm2 die in early embryogenesis, whereas mice lacking both Mdm2 and p53 are grossly normal (Jones et al. 1995; Montes de Oca Luna et al. 1995).”
BackgroundVaughan, C. A., Mohanraj, L., Singh, S. K., Dumur, C. I., Ramamoorthy, M., Garrett, C. T., Windle, B. E., Yeudall, W. A., Deb, S., & Deb, S. P. (2011) · Genes & Cancer · doi:10.1177/1947601911436008 · Cited by 17
Ganeshan, L., Li, A., & O’Neill, C. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.109.083162 · Cited by 15
“Furthermore, this phenotype can be reversed by the compound Mdm2 / Trp53 / mutation in the B6 background [32].”
BackgroundMiedl, H., Lebhard, J., Ehart, L., & Schreiber, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030509 · Cited by 16
The Janus Face of p53-Targeting Ubiquitin Ligases
Hao, Q., Chen, Y., & Zhou, X. Y. (2020) · Cells · doi:10.3390/cells9071656 · Cited by 16
Yang, Y., Bolnick, A. D., Shamir, A. M., Abdulhasan, M. A., Li, Q., Parker, G. C., Puscheck, E. E., & Rappolee, D. A. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9734-4 · Cited by 15
Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin
Smith, M. L. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006390107197 · Cited by 9
“There is substantial genetic evidence that Mdm2 may downregulate p53 activity in normal cells even in the absence of exogenous DNA damage [ 29 , 30].”
BackgroundCellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.